Based on our current understanding of the HGF/c-Met pathway in HCC, several strategies have been proposed for inhibiting HGF and/or c-Met expression or activity at different levels in HCC management [8]–[10]. The gene discussed is MET; the disease is hepatocellular carcinoma.